Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
Minerva Neurosciences has begun screening the first patient in its global Phase 3 confirmatory trial of roluperidone, a drug candidate designed to treat negative symptoms of schizophrenia such as avolition, anhedonia, and social withdrawal—symptoms for which there are currently no FDA-approved therapies. The trial plans to enroll approximately 380 …